338 related articles for article (PubMed ID: 18506634)
1. Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases.
Dejda A; Jolivel V; Bourgault S; Seaborn T; Fournier A; Vaudry H; Vaudry D
J Mol Neurosci; 2008 Nov; 36(1-3):26-37. PubMed ID: 18506634
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis.
Seaborn T; Masmoudi-Kouli O; Fournier A; Vaudry H; Vaudry D
Curr Pharm Des; 2011; 17(3):204-14. PubMed ID: 21348830
[TBL] [Abstract][Full Text] [Related]
3. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis.
Vaudry D; Pamantung TF; Basille M; Rousselle C; Fournier A; Vaudry H; Beauvillain JC; Gonzalez BJ
Eur J Neurosci; 2002 May; 15(9):1451-60. PubMed ID: 12028355
[TBL] [Abstract][Full Text] [Related]
4. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo.
Reglodi D; Kiss P; Lubics A; Tamas A
Curr Pharm Des; 2011; 17(10):962-72. PubMed ID: 21524257
[TBL] [Abstract][Full Text] [Related]
5. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death.
Vaudry D; Rousselle C; Basille M; Falluel-Morel A; Pamantung TF; Fontaine M; Fournier A; Vaudry H; Gonzalez BJ
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6398-403. PubMed ID: 11972030
[TBL] [Abstract][Full Text] [Related]
6. The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32.
Vaudry D; Gonzalez BJ; Basille M; Pamantung TF; Fontaine M; Fournier A; Vaudry H
Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13390-5. PubMed ID: 11087878
[TBL] [Abstract][Full Text] [Related]
7. [Neuroprotective role of PACAP, VIP, and PHI in the central nervous system].
Sokołowska P; Dejda A; Nowak JZ
Postepy Hig Med Dosw (Online); 2004; 58():416-27. PubMed ID: 15577749
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of PACAP in ischemia.
Reglodi D; Vaczy A; Rubio-Beltran E; MaassenVanDenBrink A
J Headache Pain; 2018 Mar; 19(1):19. PubMed ID: 29500688
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide.
Bourgault S; Vaudry D; Dejda A; Doan ND; Vaudry H; Fournier A
Curr Med Chem; 2009; 16(33):4462-80. PubMed ID: 19835562
[TBL] [Abstract][Full Text] [Related]
10. PACAP as a neuroprotective factor in ischemic neuronal injuries.
Shioda S; Nakamachi T
Peptides; 2015 Oct; 72():202-7. PubMed ID: 26275482
[TBL] [Abstract][Full Text] [Related]
11. PACAP inhibits delayed rectifier potassium current via a cAMP/PKA transduction pathway: evidence for the involvement of I k in the anti-apoptotic action of PACAP.
Mei YA; Vaudry D; Basille M; Castel H; Fournier A; Vaudry H; Gonzalez BJ
Eur J Neurosci; 2004 Mar; 19(6):1446-58. PubMed ID: 15066141
[TBL] [Abstract][Full Text] [Related]
12. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells.
Falluel-Morel A; Aubert N; Vaudry D; Basille M; Fontaine M; Fournier A; Vaudry H; Gonzalez BJ
J Neurochem; 2004 Dec; 91(5):1231-43. PubMed ID: 15569266
[TBL] [Abstract][Full Text] [Related]
13. Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases.
Polanco MJ; Pennuto M
Curr Pharm Des; 2018; 24(33):3878-3891. PubMed ID: 30479210
[TBL] [Abstract][Full Text] [Related]
14. Doxycycline exerted neuroprotective activity by enhancing the activation of neuropeptide GPCR PAC1.
Yu R; Zheng L; Cui Y; Zhang H; Ye H
Neuropharmacology; 2016 Apr; 103():1-15. PubMed ID: 26700245
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of PACAP for neurodegenerative diseases.
Yang R; Jiang X; Ji R; Meng L; Liu F; Chen X; Xin Y
Cell Mol Biol Lett; 2015 Jun; 20(2):265-78. PubMed ID: 26204407
[TBL] [Abstract][Full Text] [Related]
16. Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates.
Jolivel V; Basille M; Aubert N; de Jouffrey S; Ancian P; Le Bigot JF; Noack P; Massonneau M; Fournier A; Vaudry H; Gonzalez BJ; Vaudry D
Neuroscience; 2009 May; 160(2):434-51. PubMed ID: 19236905
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells.
Vaudry D; Falluel-Morel A; Basille M; Pamantung TF; Fontaine M; Fournier A; Vaudry H; Gonzalez BJ
J Neurosci Res; 2003 May; 72(3):303-16. PubMed ID: 12692897
[TBL] [Abstract][Full Text] [Related]
18. Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.
Bourgault S; Chatenet D; Wurtz O; Doan ND; Leprince J; Vaudry H; Fournier A; Vaudry D
Curr Pharm Des; 2011; 17(10):1002-24. PubMed ID: 21524253
[TBL] [Abstract][Full Text] [Related]
19. Pituitary adenylate cyclase-activating polypeptide (PACAP) alters parasympathetic neuron gene expression in a time-dependent fashion.
Sumner AD; Margiotta JF
J Mol Neurosci; 2008 Nov; 36(1-3):141-56. PubMed ID: 18594777
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.
Dejda A; Sokołowska P; Nowak JZ
Pharmacol Rep; 2005; 57(3):307-20. PubMed ID: 15985713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
